title: Adropin and irisin levels in relation to nutrition, body composition, and insulin resistance in patients with end-stage renal disease on chronic hemodialysis and peritoneal dialysis.
abstract: INTRODUCTION    Newly discovered myokines, adropin, and irisin, are regulators of energy homeostasis and metabolism in humans. In end-stage renal disease (ESRD), the significance and role of irisin and adropin as metabolism regulators are still unclear. OBJECTIVES    The aim of this study was to evaluate serum adropin and irisin levels and establish their relation to insulin resistance, nutritional status, and hydration status in patients on chronic hemodialysis (HD) and on peritoneal dialysis (PD). PATIENTS AND METHODS    The study consisted of 71 subjects, including 48 patients (18 women, 30 men; median age, 56.5 years; range, 26-84 years) either on HD (n = 41) or PD (n = 7) and 36 healthy controls matched for age and sex. We measured the serum levels of adropin, irisin, creatinine, albumin, glucose, and insulin, as well as the plasma levels of lipids. The bioimpedance method was used to evaluate the body composition and overhydration in patients with ESRD. RESULTS    Irisin levels were significantly lower in patients with ESRD compared with controls, but there were no differences in adropin levels between both study groups. Adropin levels were inversely correlated with body mass, lean tissue mass, total, intracellular, and extracellular water, and albumin concentrations in patients with ESRD. Irisin levels were positively correlated with glucose levels and homeostasis model assessment of insulin resistance. No significant correlations were observed between adropin and irisin concentrations and overhydration. CONCLUSIONS    Adropin may be considered as a new marker of nutritional status in patients with ESRD. The significance and cause of low irisin levels characteristic for these patients are still unclear. Adropin and irisin should be further investigated as possible markers of cachexia and insulin resistance in patients with ESRD.
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Kałużna
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Hoppe
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Schwermer
authors.forename: Aisha Y
authors.initials: AY
authors.lastname: Ibrahim
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Pawlaczyk
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Ziemnicka
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D001798:Blood Proteins; D001823:Body Composition; D005260:Female; D005353:Fibronectins / Q000097:blood*; D006801:Humans; D007333:Insulin Resistance; D036341:Intercellular Signaling Peptides and Proteins; D007676:Kidney Failure, Chronic / Q000097:blood / Q000378:metabolism / Q000503:physiopathology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009752:Nutritional Status; D010455:Peptides / Q000097:blood*; D006435:Renal Dialysis
chemical_list: D015415:Biomarkers; D001798:Blood Proteins; C568440:Enho protein, human; C577593:FNDC5 protein, human; D005353:Fibronectins; D036341:Intercellular Signaling Peptides and Proteins; D010455:Peptides